Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

Journal of Clinical Oncology

Volumn 30, Issue 28, 2012, Pages 3460-3467

  Green, Tina Marie ^a,b   Young, Ken H ^f   Visco, Carlo ^g   Xu Monette, Zijun Y ^f   Orazi, Attilio ^h   Go, Ronald S ⁱ   Nielsen, Ole ^a   Gadeberg, Ole V ^c   Mourits Andersen, Torben ^d   Frederiksen, Mikael ^e   Pedersen, Lars Møller ^a   Møller, Michael Boe ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c LILLEBAELT HOSPITAL   (Denmark)

^d ESBJERG HOSPITAL   (Denmark)

^e Haderslev Hospital   (Denmark)

^f UNIVERSITY OF TEXAS   (United States)

^g SAN BORTOLO HOSPITAL   (Italy)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON REGULATORY FACTOR 4; MYC PROTEIN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SCORING SYSTEM; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TRANSLOCATION, GENETIC; VINCRISTINE;

EID: 84867060272     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.4342     Document Type: Article

References (38)

1. Sehn LH: A decade of R-CHOP. Blood 116: 2000-2001, 2010
2. Fu K, Weisenburger DD, Choi WW, et al: Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like sub-types of diffuse large B-cell lymphoma. J Clin Oncol 26:4587-4594, 2008
3. [No authors listed]: A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
4. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511, 2000 (Pubitemid 30082188)
5. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
6. Barrans S, Crouch S, Smith A, et al: Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 28:3360-3365, 2010
7. Klapper W, Stoecklein H, Zeynalova S, et al: Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia 22:2226-2229, 2008
8. Savage KJ, Johnson NA, Ben-Neriah S, et al: MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114:3533-3537, 2009
9. Barrans SL, Evans PA, O'Connor SJ, et al: The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res 9:2133-2139, 2003 (Pubitemid 36687635)
10. Copie-Bergman C, Gaulard P, Leroy K, et al: Immunofluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: A GELA study. J Clin Oncol 27:5573-5579, 2009
11. Johnson NA, Savage KJ, Ludkovski O, et al: Lymphomas with concurrent BCL2 and MYC translocations: The critical factors associated with survival. Blood 114:2273-2279, 2009
12. Snuderl M, Kolman OK, Chen YB, et al: B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 34:327-340, 2010
13. Li S, Lin P, Fayad LE, et al: B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/ t(14;18)(q32;q21): An aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 25:145-156, 2012
14. Bea S, Zettl A, Wright G, et al: Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 106:3183-3190, 2005 (Pubitemid 41565917)
15. Lenz G, Wright GW, Emre NC, et al: Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 105:13520-13525, 2008
16. Jaffe ES, Harris NL, Stein H, et al: Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001, pp 171-174
17. Swerdlow SH, Campo E, Harris NL, et al: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4). Lyon, France, IARC Press, 2008, pp 233-237
18. Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004 (Pubitemid 38029949)
19. Green TM, Nielsen O, de Stricker K, et al: High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol 36:612-619, 2012
20. Ventura RA, Martin-Subero JI, Jones M, et al: FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn 8:141-151, 2006 (Pubitemid 43811236)
21. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007 (Pubitemid 350002966)
22. Obermann EC, Csato M, Dirnhofer S, et al: BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma. J Clin Pathol 62:903-907, 2009
23. Obermann EC, Csato M, Dirnhofer S, et al: Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment. J Clin Pathol 62:754-756, 2009
24. Kramer MH, Hermans J, Wijburg E, et al: Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92:3152-3162, 1998 (Pubitemid 28492322)
25. Iqbal J, Sanger WG, Horsman DE, et al: BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol 165:159-166, 2004 (Pubitemid 38821823)
26. Iqbal J, Meyer PN, Smith LM, et al: BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res 17:7785-7795, 2011
27. Tibiletti MG, Martin V, Bernasconi B, et al: BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: A multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Hum Pathol 40:645-652, 2009
28. van Imhoff GW, Boerma EJ, van der Holt B, et al: Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 24:4135-4142, 2006
29. Aukema SM, Siebert R, Schuuring E, et al: Double-hit B-cell lymphomas. Blood 117:2319-2331, 2011
30. Tapia G, Lopez R, Muñoz-Mármol AM, et al: Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas. Histopathology 59:672-678, 2011
31. de Jong D, Rosenwald A, Chhanabhai M, et al: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications - A study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 25:805-812, 2007 (Pubitemid 350002880)
32. Zu Y, Steinberg SM, Campo E, et al: Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma. Leuk Lymphoma 46:693-701, 2005 (Pubitemid 40775217)
33. Lejeune Mn, Jaén J, Pons L, et al: Quantification of diverse subcellular immunohistochemical markers with clinicobiological relevancies: Validation of a new computer-assisted image analysis procedure. J Anat 212:868-878, 2008
34. Wilson KS, Sehn LH, Berry B, et al: CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leuk Lymphoma 48:1102-1109, 2007 (Pubitemid 47009200)
35. Mounier N, Briere J, Gisselbrecht C, et al: Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279-4284, 2003 (Pubitemid 36857789)
36. Mounier N, Briere J, Gisselbrecht C, et al: Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. Haematologica 91:715-716, 2006 (Pubitemid 43799481)
37. Hill ME, MacLennan KA, Cunningham DC, et al: Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation Study. Blood 88:1046-1051, 1996 (Pubitemid 26333330)
38. Lossos IS, Morgensztern D: Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 24:995-1007, 2006 (Pubitemid 46638855)